Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman, Myla D Goldman, Hans-Peter Hartung, Eva Kubala Havrdová, Douglas Jeffery, Aaron Miller, Finn Sellebjerg, Diego Cadavid, Dan Mikol, Deborah Steiner, on behalf of the ASCEND investigators

Summary

Background Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses.

Methods ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181.

Findings Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred.

Interpretation Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components.

Funding Biogen.

Introduction Patients with multiple sclerosis usually present with neurological relapses and the disorder evolves to accumulate gradual disability with or without superimposed relapses in the secondary progressive phase.1 Disease-modifying treatments are increasingly available for relapsing multiple sclerosis; however, despite numerous studies,2–10 benefits in trials of progressive multiple sclerosis are modest and mostly target actively relapsing subgroups or those with lesion activity on imaging. Although recent results have suggested a treatment effect of siponimod in secondary progressive multiple sclerosis,11 only mitoxantrone has received approval for delaying disability in secondary progressive
Hospital for Neurology and Foundation Trust, London

Dr Raju Kapoor, National Correspondence to: WC1N 3BG, UK

blood–brain barrier, interferes with chemokine Natalizumab inhibits leucocyte transmigration across the inflammatory in phase 2 trials of simvastatin and methotrexate and in phase 3 trials of interferon beta-1b and mitoxantrone. Positive results on disability progression in a phase 3 trial of siponimod were recently presented in a conference abstract. In a phase 2 proof-of-concept study of natalizumab in progressive forms of multiple sclerosis, treatment reduced markers of intrathecal inflammation and tissue damage, suggesting that natalizumab might have therapeutic efficacy in progressive forms of multiple sclerosis. Retrospective analysis of outcomes in two early-phase studies of natalizumab in secondary progressive multiple sclerosis indicated non-significant improvement in ambulation. For assessment of treatment effects in progressive multiple sclerosis, the Expanded Disability Status Scale (EDSS) was found to have poor responsiveness in patients with high baseline disability scores, and detection of disability progression in secondary progressive multiple sclerosis was improved with a multicomponent endpoint consisting of the EDSS, the Timed 25-Foot Walk, and the 9-Hole Peg Test. This multicomponent endpoint might represent a better measure to detect disability progression in secondary progressive multiple sclerosis by providing similar power with approximately half the sample size.

Added value of this study

The ASCEND study is, to our knowledge, the first phase 3 trial to assess the efficacy of natalizumab on sustained disability progression in mostly non-relapsing patients with secondary progressive multiple sclerosis, and its use is restricted by substantial risks of cardiotoxicity and leukaemia. Hence, an important unmet need exists for therapies in secondary progressive multiple sclerosis that prevent disability progression unrelated to relapse.

Treatments for relapsing multiple sclerosis generally act on the peripheral immune response. Their limited effects on progressive disability suggest that the mechanisms of tissue injury are diverse in progressive multiple sclerosis. Particular interest has emerged in the intrathecal immune response, which is shielded from peripherally acting agents behind the blood–brain barrier. Natalizumab, a recombinant humanised monoclonal antibody against α4 integrin (very late antigen-4), is highly effective in relapsing-remitting multiple sclerosis and appears to suppress intrathecal inflammation. Natalizumab inhibits leucocyte transmigration across the blood–brain barrier, interferes with chemokine-mediated inflammatory-cell recruitment into the CNS, and disrupts the production of molecules required to sustain intrathecal inflammation. Results from early phase trials in progressive multiple sclerosis show that natalizumab treatment suppresses CSF markers of inflammation and neurodegeneration, including concentrations of osteopontin and the B-cell chemokine CXCL13, and suggest that treatment also improves ambulation and upper-limb function.

On the basis of these considerations, we aimed to investigate whether treatment with natalizumab is safe and slows the accumulation of disability unrelated to relapse in patients with secondary progressive multiple sclerosis.

Methods

Study design

The ASCEND study was an international, multicentre, phase 3 clinical trial done in two parts. In the randomised, double-blind, parallel-group, placebo-controlled phase...
(part 1), patients with secondary progressive multiple sclerosis from 163 sites in 17 countries received natalizumab or placebo and underwent scheduled study assessments for up to 96 weeks. The 17 countries were Belgium, Canada, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Israel, Italy, the Netherlands, Poland, Russia, Spain, Sweden, the UK, and the USA.

In the prespecified, optional open-label extension phase for safety and efficacy (part 2), all patients who completed part 1 could receive natalizumab until the end of the study. Patients who did not enrol in part 2 stopped blinded study treatment at week 96 and returned to the study site for a follow-up visit at week 108. Patients who opted to enrol in part 2 continued to receive blinded study treatment every 4 weeks between enrolment into part 2 (week 96) and the start of open-label treatment at week 108. In the protocol, the overall end of the study was defined as the last patient’s final visit for collection of data in part 2. However, part 2 was terminated by the after the results of part 1 were released, before completion of year 4 of the study, because a significant effect on the primary multicomponent endpoint in part 1 was not observed. Because of the premature trial termination, the efficacy analysis was based on data collected up to week 156.

The ASCEND study was done in accordance with the Declaration of Helsinki, the International Conference on Harmonisation, and good clinical practice guidelines. Approval for the study protocol, including any amendments, was granted by each centre’s ethics committee, and all patients provided written informed consent before initiating any study-related activities.

An independent drug safety monitoring committee reviewed interim unblinded safety data for part 1 of the study. This committee met quarterly to review safety data and to advise on changes in study design. This committee was also charged with determining whether the study should be stopped or amended for reasons other than safety.

Participants
Natalizumab-naive patients aged 18–58 years were eligible for enrolment in part 1 of the ASCEND study if they had onset of secondary progressive multiple sclerosis 2 or more years before enrolment, an Expanded Disability Status Scale (EDSS) score of 3.0–6.5 (inclusive), a Multiple Sclerosis Severity Score of 4 or more, and disability progression not related to clinical relapses during the year before enrolment, as assessed by clinical historical findings with a standardised form (appendix). Unlike previous secondary progressive multiple sclerosis trials that enrolled patients with recent clinical relapses, ASCEND excluded patients who had a clinical relapse up to 3 months before randomisation (to prevent recent relapses from influencing the baseline assessment of disability). A full list of part 1 inclusion and exclusion criteria is included in the appendix.

For inclusion in part 2, eligible patients were required to have participated in part 1 and to have completed all part 1 examinations and efficacy assessments before receiving the first open-label dose at week 108 in part 2. Patients were excluded from part 2 if they had discontinued study treatment, received less than 20 infusions, or missed two or more consecutive infusions in part 1.

Randomisation and masking
In part 1 of ASCEND, eligible patients were randomly assigned (1:1) to receive natalizumab or placebo of identical appearance. Patients were stratified by site and EDSS score (3.0–5.5 vs 6.0–6.5). Patients and study staff were masked to treatment assignments in part 1, and patients enrolling in part 2 also received blinded study treatment during weeks 100 and 104. Patients in part 2 received open-label treatment starting in week 108. Both patients and study staff remained masked to the treatment assignments in part 2. Only the pharmacist preparing the infusion and the pharmacy study monitors were not masked to the study treatment, which was stored in a secure location and accounted for by the investigator. Patients were randomly assigned by an interactive voice/web response system (IXRS, Bracket Global LLC, San Francisco, CA, USA).

Procedures
In part 1, patients received 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. In the open-label extension phase in part 2, all patients received 300 mg intravenous natalizumab every 4 weeks until the end of the study. In part 1, EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT) assessments were done at baseline and every 12 weeks up to week 108. Additional details of T25FW, 9HPT, and MRI assessments are provided in the appendix. During part 2, EDSS, T25FW, and 9HPT assessments were done at week 156. The last progression events that could be confirmed in part 1 started at week 84, with final confirmation at week 108 (appendix). The additional progression events ascertained in part 2 were possible progression starting at weeks 96 and 108, when patients who entered part 2 were still being treated with their blinded therapy assignments from part 1. Because of the premature trial termination, events at weeks 96 and 108 were confirmed at week 156 for patients in part 2, during which all patients were treated with open-label natalizumab.

Patients underwent a blood test for presence of anti-JC virus (JCV) antibodies at baseline and every 24 weeks during parts 1 and 2. As per the study protocol, the principal investigator received anti-JCV antibody results throughout the study. Investigators were informed of a patient’s anti-JCV antibody status before enrolment in part 2 and at 24 week intervals thereafter.

Treatment-emergent adverse events and serious adverse events were recorded in the safety population during parts 1 and 2. Over the course of parts 1 and 2 (every 12 weeks up
Part 2 was terminated by the funder after the results of part 1 were released. At week 156, progression was confirmed whether patients had a protocol-defined relapse. All reviews were done without knowledge of the patient’s treatment assignment and without an MRI scan.

**Outcomes**

The primary outcome in part 1 was based on a multicomponent measure of sustained disability progression comprising the EDSS, T25FW, and 9HPT, and was designed to provide a more sensitive and specific measure of disease worsening in secondary progressive multiple sclerosis than EDSS alone.21 The primary endpoint was the proportion of patients with confirmed disability progression over the 96 week treatment period, with progression defined as meeting one or more of the following three criteria: an increase of 1-0 points or more from a baseline score of 5·5 or lower or an increase of 0-5 points or more from a baseline score of 6·0 or higher on the EDSS; an increase of 20% or more from baseline on the T2FW; or an increase of 20% or more from baseline (on either hand) on the 9HPT. Progression was confirmed at a subsequent visit 6 or more months after the start of a possible progression and at the end of the trial. To minimise the possibility of capturing disability progression due to clinical relapses, included disability progression events could not start or be confirmed 74 or fewer days following onset of an INEC-confirmed clinical relapse. The primary endpoint in part 2 was the incidence of adverse events and serious adverse events in patients with secondary progressive multiple sclerosis.

In part 1, secondary endpoints included the proportion of patients with consistent improvement in T2FW, change in patient-reported ambulatory status as measured by the 12-item Multiple Sclerosis Walking Scale (MSWS-12), change in patient-reported manual ability based on the ABILHAND questionnaire,22 the effect of natalizumab on patient-reported quality of life with the Multiple Sclerosis Impact Scale-29 (MSIS-29) physical score, change in whole brain volume between week 24 and week 96, and the proportion of patients with disability progression measured by individual physical EDSS functional system scores. Part 2 secondary endpoints included the proportion of patients with disability progression on the multicomponent endpoint confirmed during the additional follow-up time in part 2; change in T2FW, 9HPT; and EDSS from part 1 baseline to week 156; change in whole brain volume from part 1 week 24 to week 156; change in grey matter brain volume from part 1 baseline to week 156; change in number of T2 lesions from part 1 baseline to week 156; change in grey matter brain volume from part 1 baseline to week 156; and was designed to provide a more sensitive and specific measure of disease worsening in secondary progressive multiple sclerosis than EDSS alone.21 The primary endpoint was the proportion of patients with confirmed disability progression over the 96 week treatment period, with progression defined as meeting one or more of the following three criteria: an increase of 1-0 points or more from a baseline score of 5·5 or lower or an increase of 0-5 points or more from a baseline score of 6·0 or higher on the EDSS; an increase of 20% or more from baseline on the T2FW; or an increase of 20% or more from baseline (on either hand) on the 9HPT. Progression was confirmed at a subsequent visit 6 or more months after the start of a possible progression and at the end of the trial. To minimise the possibility of capturing disability progression due to clinical relapses, included disability progression events could not start or be confirmed 74 or fewer days following onset of an INEC-confirmed clinical relapse. The primary endpoint in part 2 was the incidence of adverse events and serious adverse events in patients with secondary progressive multiple sclerosis.

In part 1, secondary endpoints included the proportion of patients with consistent improvement in T2FW, change in patient-reported ambulatory status as measured by the 12-item Multiple Sclerosis Walking Scale (MSWS-12), change in patient-reported manual ability based on the ABILHAND questionnaire,22 the effect of natalizumab on patient-reported quality of life with the Multiple Sclerosis Impact Scale-29 (MSIS-29) physical score, change in whole brain volume between week 24 and week 96, and the proportion of patients with disability progression measured by individual physical EDSS functional system scores. Part 2 secondary endpoints included the proportion of patients with disability progression on the multicomponent endpoint confirmed during the additional follow-up time in part 2; change in T2FW, 9HPT; and EDSS from part 1 baseline to week 156; change in whole brain volume from part 1 week 24 to week 156; change in grey matter brain volume from part 1 baseline to week 156; change in number of T2 lesions from part 1 baseline to week 156; change in grey matter brain volume from part 1 baseline to week 156; and was designed to provide a more sensitive and specific measure of disease worsening in secondary progressive multiple sclerosis than EDSS alone.21 The primary endpoint was the proportion of patients with confirmed disability progression over the 96 week treatment period, with progression defined as meeting one or more of the following three criteria: an increase of 1-0 points or more from a baseline score of 5·5 or lower or an increase of 0-5 points or more from a baseline score of 6·0 or higher on the EDSS; an increase of 20% or more from baseline on the T2FW; or an increase of 20% or more from baseline (on either hand) on the 9HPT. Progression was confirmed at a subsequent visit 6 or more months after the start of a possible progression and at the end of the trial. To minimise the possibility of capturing disability progression due to clinical relapses, included disability progression events could not start or be confirmed 74 or fewer days following onset of an INEC-confirmed clinical relapse. The primary endpoint in part 2 was the incidence of adverse events and serious adverse events in patients with secondary progressive multiple sclerosis.

In part 1, secondary endpoints included the proportion of patients with consistent improvement in T2FW, change in patient-reported ambulatory status as measured by the 12-item Multiple Sclerosis Walking Scale (MSWS-12), change in patient-reported manual ability based on the ABILHAND questionnaire,22 the effect of natalizumab on patient-reported quality of life with the Multiple Sclerosis Impact Scale-29 (MSIS-29) physical score, change in whole brain volume between week 24 and week 96, and the proportion of patients with disability progression measured by individual physical EDSS functional system scores. Part 2 secondary endpoints included the proportion of patients with disability progression on the multicomponent endpoint confirmed during the additional follow-up time in part 2; change in T2FW, 9HPT; and EDSS from part 1 baseline to week 156; change in whole brain volume from part 1 week 24 to week 156; change in grey matter brain volume from part 1 baseline to week 156; change in number of T2 lesions from part 1 baseline to week 156; and was designed to provide a more sensitive and specific measure of disease worsening in secondary progressive multiple sclerosis than EDSS alone.21 The primary endpoint was the proportion of patients with confirmed disability progression over the 96 week treatment period, with progression defined as meeting one or more of the following three criteria: an increase of 1-0 points or more from a baseline score of 5·5 or lower or an increase of 0-5 points or more from a baseline score of 6·0 or higher on the EDSS; an increase of 20% or more from baseline on the T2FW; or an increase of 20% or more from baseline (on either hand) on the 9HPT. Progression was confirmed at a subsequent visit 6 or more months after the start of a possible progression and at the end of the trial. To minimise the possibility of capturing disability progression due to clinical relapses, included disability progression events could not start or be confirmed 74 or fewer days following onset of an INEC-confirmed clinical relapse. The primary endpoint in part 2 was the incidence of adverse events and serious adverse events in patients with secondary progressive multiple sclerosis.
confirmed T25FW/9HPT progressors versus non-progressors. Additionally, a sensitivity analysis of confirmed progression on T25FW at thresholds other than 20% (25%, 30%, 40%, and 50%) was done. Annualised relapse rate (ARR) was assessed, as was change from baseline over time for gadolinium (Gd+) lesions. The number and volume of new and enlarging T2 lesions were assessed throughout the study. Finally, disability outcomes were assessed for subgroups with or without baseline Gd+ lesions and relapses in the 1–2 years before entering the study.

**Statistical analysis**

Baseline data were described with summary statistics. Treatment comparisons for efficacy endpoints were assessed with two-sided tests at a significance level of 0.05. A closed testing procedure was used to adjust for multiple secondary endpoints. All part 1 efficacy analyses were done in the part 1 intention-to-treat population, defined as all randomly assigned patients treated at baseline. The part 2 intention-to-treat population comprised all patients who were randomly assigned in part 1 and received one or more infusions of the study treatment in part 2. The primary endpoint of the percentage of patients with confirmed progression was analysed by use of logistic regression with baseline EDSS (≤5.5 or ≥6.0), T25FW, and 9HPT of each hand as covariates. A sensitivity analysis of the primary endpoint based on time to confirmed progression was done with a Cox proportional-hazards model with baseline EDSS (≤5·5 or ≥6·0), T25FW, and 9HPT of each hand as covariates. Time to confirmed progression was defined as the time from the first infusion of study treatment to the first onset of possible progression that was subsequently confirmed. For secondary and exploratory endpoints, analysis of covariance and mixed-effects models for repeated measures were used to analyse continuous outcomes, with baseline measurement and baseline EDSS (≤5·5 or ≥6·0) as covariates, and logistic regression was used for dichotomous outcomes. For all exploratory analyses, all p values cited should be considered nominal unless otherwise stated.

The sample size was based on an assumed rate of confirmed disability progression over the 2 year period of 28% for the natalizumab group versus 40% for the placebo group—a 30% reduction. We estimated that 856 patients (428 per group) would provide 90% power at the 0·05 level of significance with a two-sided χ² test, assuming a 20% dropout rate during the study.

This trial is registered with ClinicalTrials.gov, number NCT01416181.

**Role of the funding source**

The funder initiated and provided funding for this study and drafted and provided medical writing and editorial support in the development of this manuscript. The funder was also involved in study design, data collection, data analysis, and data interpretation, and reviewed and provided feedback on this manuscript. The authors, who include both employees of the funder and academic investigators, had full editorial control of this manuscript and provided final approval of all content. The corresponding author had full access to the study data and

### Table 1: Baseline clinical characteristics of the intention-to-treat population

<table>
<thead>
<tr>
<th>Part 1</th>
<th>Part 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (n=448)</td>
<td>Natalizumab 300 mg (n=439)</td>
</tr>
<tr>
<td><strong>Age, years</strong></td>
<td></td>
</tr>
<tr>
<td>47·2 (7·8)</td>
<td>47·3 (7·4)</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td></td>
</tr>
<tr>
<td>280 (63%)</td>
<td>270 (62%)</td>
</tr>
<tr>
<td><strong>Men</strong></td>
<td></td>
</tr>
<tr>
<td>168 (37%)</td>
<td>169 (38%)</td>
</tr>
<tr>
<td><strong>Years since first multiple sclerosis symptoms</strong></td>
<td></td>
</tr>
<tr>
<td>16·2 (7·8)</td>
<td>16·8 (7·6)</td>
</tr>
<tr>
<td><strong>Years since secondary progressive multiple sclerosis diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td>4·9 (3·7)</td>
<td>4·7 (3·0)</td>
</tr>
<tr>
<td><strong>Years since most recent relapse before study</strong></td>
<td></td>
</tr>
<tr>
<td>4·8 (4·4)*</td>
<td>4·7 (4·1)*</td>
</tr>
<tr>
<td><strong>Median EDSS score</strong></td>
<td></td>
</tr>
<tr>
<td>6·0 (5·0–6·5)</td>
<td>6·0 (5·0–6·5)</td>
</tr>
<tr>
<td><strong>Patients with EDSS score of 3·0–5·5</strong></td>
<td></td>
</tr>
<tr>
<td>166 (37%)</td>
<td>165 (38%)</td>
</tr>
<tr>
<td><strong>Patients with EDSS score of 6·0–6·5</strong></td>
<td></td>
</tr>
<tr>
<td>282 (63%)</td>
<td>274 (62%)</td>
</tr>
<tr>
<td><strong>Median T25FW, s</strong></td>
<td></td>
</tr>
<tr>
<td>11·2 (7·9–16·8)</td>
<td>11·2 (7·9–17·5)</td>
</tr>
<tr>
<td><strong>Median 9HPT, s</strong></td>
<td></td>
</tr>
<tr>
<td>28·8 (23·8–36·6)</td>
<td>28·2 (23·5–36·4)</td>
</tr>
<tr>
<td><strong>Non-dominant hand</strong></td>
<td></td>
</tr>
<tr>
<td>29·6 (24·7–40·2)</td>
<td>29·6 (25·0–38·5)</td>
</tr>
<tr>
<td><strong>Patients with Gd+ lesions</strong></td>
<td></td>
</tr>
<tr>
<td>96 (22%)†</td>
<td>114 (26%)†</td>
</tr>
<tr>
<td><strong>T2 lesion volume, cm³</strong></td>
<td></td>
</tr>
<tr>
<td>16·2 (16·4)†</td>
<td>17·4 (17·6)†</td>
</tr>
<tr>
<td><strong>Normalised whole brain volume, cm³</strong></td>
<td></td>
</tr>
<tr>
<td>142·5 (83·1)†</td>
<td>1420·9 (82·8)§</td>
</tr>
</tbody>
</table>

Data are n (%), mean (SD), or median (IQR). EDSS=Expanded Disability Status Scale. Gd+=gadolinium enhancing. T25FW=Timed 25-Foot Walk. 9HPT=9-Hole Peg Test. *n=430 for placebo; n=431 for natalizumab. †n=446 for placebo; n=438 for natalizumab. §n=444 for placebo; n=436 for natalizumab.
had final responsibility for the decision to submit for publication.

Results
Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned in part 1, and 888 patients received at least one infusion of the study drug (natalizumab, n=439; placebo, n=449; figure 1). 887 patients were included in the part 1 intention-to-treat population (natalizumab, n=439; placebo, n=448). One placebo-treated patient received the first dose at week 28 and was therefore not included in the part 1 intention-to-treat population. 655 (74%) patients (natalizumab, n=336; placebo, n=319) completed treatment through to week 96, and 638 (72%) patients (natalizumab, n=326; placebo, n=312) completed the study through to the end of part 1 (week 108). Following part 1, 566 patients continued into part 2 (continuing natalizumab, n=292; initiating natalizumab, n=274), and 565 patients received the study drug and were included in the part 2 intention-to-treat population (continuing natalizumab, n=291; initiating natalizumab, n=274). In part 2, the first treatment was received on Dec 2, 2013, and the study ended on April 13, 2016. The median total follow-up time, including the 96 weeks of part 1, was 157 weeks (range 108–221) for patients initiating natalizumab (switching from placebo) and 160 weeks (118–213) for patients continuing natalizumab.

At baseline for part 1, clinical characteristics were balanced between treatment groups. Characteristics were also balanced between patients from part 1 and those who enrolled into part 2 (table 1). Baseline characteristics were generally similar between patients in the ASCEND part 1 intention-to-treatment population who entered part 2 and those who did not (appendix). In the part 1 intention-to-treatment population (n=887), the mean time since first multiple sclerosis symptoms was 16·5 (SD 7·7) years. At baseline, ambulatory impairment was present in all patients and was advanced in the majority; 556 (63%) patients had EDSS scores of 6·0–6·5 (requiring walking aid) and only 13 (1%) patients had an EDSS score of 3·0 (n=7 for natalizumab, n=6 for placebo). The overall mean baseline EDSS score was 5·6 (SD 0·9). As intended by the study design, enrolled patients with secondary progressive multiple sclerosis had minor relapse activity; 744 (84%) were relapse-free within the year before baseline assessment (n=373 for the natalizumab group, n=371 for the placebo group) and 627 (71%) were relapse-free within the 2 years before baseline assessment (n=312 for the natalizumab group, n=315 for the placebo group).

ASCEND did not meet the primary endpoint for part 1 assessed at 2 years (figure 2). The proportion of confirmed progressors on the primary endpoint was lower in the natalizumab group (195 [44%] of 439) than in the placebo group (214 [48%] of 448), but the difference was not significant (p=0·287). No treatment effect was observed on two components of the primary endpoint that measure progression of ambulatory disability: EDSS and T25FW (figure 2). However, natalizumab treatment was associated with a nominally significant 4% reduction in the relative risk of confirmed upper-limb disability progression as measured by 9HPT; the third component of the primary endpoint (64 [15%] with natalizumab vs 104 [23%] with placebo; adjusted odds ratio [OR] 0·56 [95% CI 0·40–0·80]; p=0·001; figure 2).

In part 1, no significant differences between treatment groups in the change from baseline to year 2 were seen in any of the secondary endpoints, including MSWS-12, ABILHAND, and MSIS-29 (appendix). From week 24 to week 96 in part 1, the mean percentage change in whole brain volume was −0·66% (SD 0·60) in natalizumab-treated patients and −0·72% (0·66) in placebo-treated patients (p=0·242).

Exploratory analyses suggested that the effect of natalizumab on slowing upper-limb disability accumulation as measured by 9HPT in part 1 was observed regardless of baseline Gd+ lesions and was apparent in patients without relapses in the 1–2 years before the study (appendix), although differences between subgroups were not significant.

In additional exploratory analyses, natalizumab improved the ARR and outcomes of MRI endpoints compared with placebo (appendix).

In part 1, 410 (91%) patients in the placebo group and 401 (91%) in the natalizumab group reported one or more...
adverse events (table 2). Overall, adverse events were similar between natalizumab-treated and placebo-treated patients in part 1 (table 2). Natalizumab was generally well tolerated, with observed adverse events consistent with the known safety profile of natalizumab at the approved dose (300 mg every 4 weeks).15 Table 3 shows all serious adverse events occurring in 1% or more patients in both treatment groups; all serious adverse events occurring in one or more patients are reported in the appendix. In part 1, the proportion of patients reporting a serious adverse event was similar for the two treatment groups (90 [20%] for natalizumab vs 100 [22%] for placebo; table 3). Multiple sclerosis relapse was the most frequently reported serious adverse event in the two treatment groups, occurring in 21 (5%) patients in the natalizumab group versus 28 (6%) in the placebo group. The only other serious adverse events reported in 1% or more patients in either treatment group were urinary tract infection (five [1%] in the natalizumab group vs 12 [3%] in the placebo group), fall (six [1%] vs three [<1%]), and pneumonia (two [<1%] vs five [1%]; table 3). During the course of part 1, two patients receiving natalizumab died: one of lung cancer, and the other of septic shock with multiple organ failure. The investigators assessed both events to be unrelated to study treatment.

For the part 2 primary endpoint, 245 (84%) patients continuing natalizumab and 250 (91%) initiating natalizumab reported one or more adverse events (table 2). Adverse events were generally similar among patients continuing natalizumab and those initiating natalizumab in part 2 (table 2). No deaths occurred in part 2, and serious adverse events were reported by 39 (13%) patients continuing natalizumab and 24 (9%) initiating natalizumab (table 3). As in part 1, multiple sclerosis relapse was the most frequently reported serious adverse event, occurring in five (2%) patients in each group. No cases of progressive multifocal leukoencephalopathy occurred in part 1 or 2, and no new safety concerns were identified during the course of the study.

For secondary efficacy analyses in part 2, the proportion of patients who progressed on the multicomponent endpoint was lower in the natalizumab-treated group than in the placebo-treated group (150 [52%] vs 167 [61%]; adjusted OR 0.67 [95% CI 0.47–0.94]; p=0.021; figure 2). As in part 1, upper-limb progression assessed by 9HPT in part 2 was lower in patients continuing natalizumab than in those initiating natalizumab (55 [19%] vs 78 [28%]; adjusted OR 0.59 [95% CI 0.39–0.88]; p=0.009; figure 2). All other secondary endpoints in part 2 did not show a treatment effect. An exploratory analysis done with Kaplan-Meier estimates of the cumulative probability, over 156 weeks, of time to confirmed progression on the multicomponent endpoint (including the total part 1 intention-to-treat population, with data from patients who did not enrol in part 2 censored at week 108) showed significantly increased separation over time between patients originally
randomly assigned to natalizumab and those randomly assigned to placebo who initiated natalizumab at week 108 (52·1% vs 64·2%; p=0·010; figure 3).

MRI endpoints based on focal inflammation in part 2 are shown in the appendix. During part 2, the risk of relapse was 39·3% lower for patients continuing natalizumab than for those initiating natalizumab (ARR 0·11 vs 0·19; rate ratio 0·607 [95% CI 0·424–0·868]; p=0·006).

Discussion
During the 2 year randomised treatment stage (part 1) of this phase 3 clinical trial, natalizumab did not significantly reduce disability progression as assessed by the primary multicomponent endpoint and secondary endpoints in patients with secondary progressive multiple sclerosis. However, progression of the upper-limb component of the primary disability endpoint, as assessed by 9HPT, was reduced in both parts 1 and 2. Significant efficacy was also observed on reductions in ARR and MRI measures of focal inflammation, as expected from previous trials in patients with relapsing-remitting multiple sclerosis. Imaging studies showed that treatment did not affect loss of whole brain volume during part 1, but that whole brain volume loss was significantly lower when considering parts 1 and 2 together or part 2 separately.

Interpretation of the positive treatment effects in part 2 is limited by the fact that this was an open-label extension phase of ASCEND and that the study was not designed with part 1 as an interim analysis. Significance was not achieved on the primary endpoint during part 1; therefore, significance in part 2 is only nominal, since adjustments for multiplicity were not applied. Furthermore, because of early termination, part 2 did not last for the planned 2 years beyond the end of part 1. This early closure might have precluded detection of outcomes requiring a longer period of time to show a treatment effect. It should also be noted that, for part 1, disability progression was required to be confirmed not only at a visit 6 or more months later, with the period of 3 months following onset of an adjudicated clinical relapse excluded, but also at week 96. This is possibly the most stringent requirement for verification of progression adopted for progressive multiple sclerosis trials to date.

During part 1, the attrition rate was somewhat higher than expected (638 [72%] of 888 patients completed 108 weeks, so the dropout rate [28%] was higher than the predicted dropout of 20%). However, the numbers of patients in each treatment group who completed the study were similar (n=326 for natalizumab vs n=312 for placebo). Additionally, it was prespecified that possible disability progression for patients who discontinued could be confirmed on the basis of the discontinuation visit measurements, and progression could also be considered confirmed if patients discontinued treatment because of inadequate efficacy (at the discretion of the investigator). The effect of attrition on the validity of the conclusions is therefore limited. Patients in part 2 were a subset of the original randomised population, and disability measurements for those not continuing to part 2 were incomplete because of early termination of that phase of the trial, so selection bias could have occurred. However, patients who did or did not enter the open-label extension had similar baseline characteristics and disability progression outcomes in part 1, suggesting that selection bias was minimal. Bias was limited further by maintaining full masking to the initial treatment allocation through the open-label extension. Masking was also maintained for the imaging measurements, although bias might have occurred because of pseudoatrophy affecting whole brain matter volume in patients newly initiating natalizumab in part 2.

In contrast to several previous trials in secondary progressive multiple sclerosis, ASCEND enrolled patients with predominantly non-relapsing secondary progressive multiple sclerosis, who constitute a multiple sclerosis population with high unmet needs. Furthermore, at baseline, the majority of ASCEND patients had advanced disability with ongoing disease progression unrelated to relapses: 63% had EDSS scores of 6·0–6·5, and 71% had no relapses in the 2 years before baseline assessment. The on-study ARR in patients randomly assigned to placebo was low (0·17 [95% CI 0·14–0·21]; appendix), further supporting the low relapsing activity of the enrolled population. These patients represent the secondary progressive multiple sclerosis population for whom no effective therapy is available to delay or prevent further disability progression unrelated to relapses.

Detecting change with available validated outcome measures in a slowly progressing multiple sclerosis population over a short period of observation is difficult. The multicomponent endpoint used in this study might be more sensitive to changes in disability than the EDSS alone, but two of its three components focus on lower-limb function and were not affected by treatment. The EDSS, in particular, has been shown to have poor responsiveness to disease progression and treatment effects in patients with high baseline scores. Other studies in patients with secondary progressive multiple sclerosis have used composite outcome measurements and reported differences in outcomes assessing upper-limb versus lower-limb function, highlighting the importance of using sensitive measures of disease worsening in secondary progressive multiple sclerosis trials that include key domains of function in addition to ambulation.

In part 1 of this study, we observed an apparent beneficial effect of natalizumab on limb function but not on measures of ambulation. Although this difference could be explained by different treatment effects on neural systems serving different functions, the findings are also consistent with the possibility that the benefits of stopping inflammation from further damaging the CNS...
manifest after a delay that is shorter in pathways with shorter axons than in pathways with longer axons.\textsuperscript{26} Axons undergoing injury might continue to degenerate even after the mechanisms of injury are inhibited by treatment (eg, from trans-synaptic degeneration or because demyelination renders them vulnerable to injury). Delayed clinical and imaging responses have been observed in trials of interferon beta and natalizumab,\textsuperscript{27,28} and are apparent in the results of the open-label phase of the ASCEND trial. Residual degeneration should abate more quickly in shorter axon pathways than in longer ones because shorter axons have a lower lesion burden. If the resulting length-dependent therapeutic lag does exist, future trial designs might need to consider longer treatment phases to capture benefits in all key aspects of disability and to plan for domain-specific outcome measures, which will respond at successively later stages in the trial.

In general, the delay in appearance of any treatment effects in patients with secondary progressive multiple sclerosis differs substantially from the rapid onset of the effects of natalizumab in patients with relapsing-remitting multiple sclerosis,\textsuperscript{29} suggesting a difference in the underlying disease mechanisms of relapsing-remitting and secondary progressive multiple sclerosis with regard to their response to α4 integrin antagonism. The observation that the beneficial effects of natalizumab on upper-limb disability progression occurred regardless of baseline Gd+ lesions or relapses before entry further suggests that treatment effects in secondary progressive multiple sclerosis might occur through different mechanisms to those observed in relapsing-remitting multiple sclerosis.

Natalizumab was generally well tolerated throughout both parts of ASCEND. No new or unexpected safety concerns were associated with its use in a secondary progressive multiple sclerosis population, and the observed safety profile was consistent with that of previous studies of natalizumab in patients with relapsing-remitting multiple sclerosis.\textsuperscript{30} The beneficial effects of natalizumab on ARR and on new and active brain lesions in ASCEND were also consistent with previous findings in patients with relapsing multiple sclerosis,\textsuperscript{31} and with continued anti-inflammatory activity in secondary progressive multiple sclerosis.\textsuperscript{32} However, natalizumab is not approved for treatment of patients with non-relapsing secondary progressive multiple sclerosis, and its benefit–risk profile has only been examined for treatment of patients with relapsing forms of multiple sclerosis.

The results of the 9HPT analyses consistently suggest that natalizumab delays loss of upper-limb function, and exploratory analyses suggest that this treatment effect occurred independently of active brain lesions (appendix). The 20% threshold of change in the 9HPT used in the primary endpoint in this study is consistent with that of previous work, which indicates that this difference corresponds to a clinically meaningful change in upper-limb function.\textsuperscript{33} Upper-limb function correlates independently with quality of life\textsuperscript{34} and is a strong predictor of treatment costs in multiple sclerosis.\textsuperscript{35} Preservation of upper-limb function ranks highly among treatment benefits desired by disabled patients with multiple sclerosis, in some instances more highly than lower-limb function for maintenance of independence. Patients also consider that those confined to wheelchairs should not be excluded from future clinical trials in progressive multiple sclerosis.\textsuperscript{36} Treatments that can preserve ability in a single functional domain could, therefore, still be valuable for patients with secondary progressive multiple sclerosis in real-world settings.

**Contributors**

DLA, MSF, MDG, H-PH, EKH, DJ, RK, AM, FS, DC, AD, DM, and DS contributed to study design. DC, DS, and BY administered the study. DLA, MSF, MDG, H-PH, EKH, DJ, RK, AM, FS, DC, AD, DM, and DS contributed to data collection. IC, FF, and NL did the data analysis. DLA, MS, MDG, H-PH, EKH, DJ, RK, AM, FS, DC, NC, IC, AD, FF, NL, DM, DS, BY, and PR-H contributed to interpretation of the data. All authors read and approved the final manuscript.

**ASCEND investigators group**

Declaration of interests
RK has received support from the NIH IRB Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London (UCLH/UCL) and personal compensation for consultancies, lectures, participation in advisory boards, and support for travel to medical meetings from Biogen, Genzyme, Karo Bio, Novartis, Roche, and Teva. UCL Hospitals received payment for investigation and follow-up of participants in the ASCEND trial. P-RH, NC, IC, AD, FF, NL, BY, and DS are employees of and hold stock or stock options, or both, in Biogen. DLA has served on advisory boards, received speaker honoraria, served as a consultant for, or received research support from, Adelphi, Biogen, Genentech, MediDay, Novartis Pharma AG, Pfizer, Receptos/Cellgene, Roche, and Sanofi, and holds stock in NeuroRx Research. MSF has received honoraria or consulting fees from Actelion, Bayer HealthCare, Clene Nanomedicine, Hoffman-La Roche, Merck Serono, Sanofi, Genzyme, and Teva Canada Innovation; participated in company advisory boards, steering committees, or boards of directors for Actelion, Bayer HealthCare, Chugui, EMD Serono, and Sanofi Genzyme; received travel support from Biogen; and received grants for research from Sanofi Genzyme. MDG has received personal compensation for consulting services from Acorda Therapeutics, Adamas, AtlasD, EMD Serono, Endoce, Genzyme, Novartis, and Serepta; honorarium from the American Academy of Neurology; and research support from Biogen, Novartis Pharmaceuticals, NMSS, and NINDS. H-PH has received personal compensation for consulting services and speaking at scientific symposia from Biogen, GeNeuro, Genzyme, Merck Serono, Novartis, Octapharma, Opera, Roche, and Teva. EKH has received research support from Biogen and The Czech Ministry of Education (project PROGRESQ27/FL1) and honoraria from Actelion, Biogen, Cellgene, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Teva. DJ has received research funding from Biogen, Genentech, and Novartis, and personal compensation for speaking or consulting services from Acorda, Bayer, Biogen, Genentech, Mallinckrodt, Novartis, Sanofi Genzyme, Serono, and Teva. AM has received research funding from Biogen, Genentech, Genzyme, Novartis, Roche, and Sanofi and personal compensation for consulting services from Accordant Health Services, Adamas, Biogen, Cellgene, Genentech, Mallinckrodt, Mapis-Pharma, Novartis, and Roche. FS has served on scientific advisory boards, on steering committees of clinical trials, or as a consultant for, or received support for, congress participation, speaker honoraria, or research support for his laboratory from Biogen, Genzyme, Merck Serono, Novartis, and Sanofi. DC was an employee of Biogen at the time of this analysis and is now an employee of Fulcrum Therapeutics. DM was an employee of Biogen at the time of this analysis and is now an employee of Amgen. Fulcrum Therapeutics, and Amgen were not in any way associated with this study.

Acknowledgments
Diogo Amarante (Biogen, Cambridge, MA), who contributed substantially to the acquisition, analysis, and interpretation of ASCEND data, passed away before development of this manuscript and therefore cannot qualify for authorship as per International Committee of Medical Journal Editors (ICMJE) criteria. We gratefully acknowledge his contributions to this manuscript, as well as the contributions of Thorsten Eickenhorst, a medical director for the study, who passed away before the development of this manuscript. All named authors meet the ICMJE criteria for authorship for this manuscript and take responsibility for the integrity of the work as a whole. Biogen provided funding for medical writing support in the development of this manuscript; Alexandra W Davis (Ashfield Healthcare Communications, Middletown, CT, USA) wrote the first draft of this manuscript based on input from authors, and Joshua Safran (Ashfield Healthcare Communications) copyedited and styled the manuscript as per journal requirements. Biogen reviewed and provided feedback to the manuscript to the authors. The authors had full editorial control of the manuscript and provided their final approval of all content.

References